Respiratory Medicine and Science

K. Bednarska, E. Hallmann-Szelińska, K. Kondratiuk, D. Rabczenko, L. B. Brydak, Bednarska, K., Hallmann-Szelińska, E., Kondratiuk, K., Rabczenko, D., Brydak, L. B.

From the time of the Hong Kong pandemic of 1968-1969, vaccines against influenza are trivalent, containing two subtypes of influenza type A: A/H1N1/ and A/H3N2/, and influenza type B. In 1980, circulation of the new Yamagata and Victoria lineages of influenza B virus was noted. Since both lineages have continued to circulate, the second lineage of influenza B was included into the trivalent vaccine as of the 2013/2014 epidemic season. In Poland, co-circulation of influenza type A and B has been registered over many seasons, although type A has predominated. According to the ACIP recommendations, quadrivalent vaccines against influenza are administered in some continents due to circulation of the B-Yamagata and B-Victoria lineages. Currently, only trivalent vaccines against influenza are available in Poland. The aim of the present research was to determine which of the two influenza type B lineages, or possibly both, would be isolated in Poland. The study was conducted with the use of real-time RT-PCR. Generally, in the 2014/2015 epidemic season in Poland, circulation of type B virus was confirmed in 34 % of influenza cases. A total of 89 specimens of influenza B were tested, including co-infections of influenza B with influenza A subtypes: A/H1N1/pdm09 and A/H3N2/. The findings were that only lineage B-Yamagata circulates in the Polish population. Therefore, vaccines available on the Polish market do not require the introduction of a fourth component.